NCT05600998 is a NA clinical trial of Camrelizumab in Ovarian Clear Cell Carcinoma, sponsored by Peking University Third Hospital.

Who is sponsoring NCT05600998?

NCT05600998 is sponsored by Peking University Third Hospital.

What drugs are being tested in NCT05600998?

Interventions in NCT05600998: Camrelizumab.

What condition does NCT05600998 study?

NCT05600998 studies Ovarian Clear Cell Carcinoma.

Is NCT05600998 still recruiting?

NCT05600998 is currently status unknown. Last updated 1 November 2022.

Last reviewed 2022-11-01 · How we verify

NCT05600998

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma

Status unknown NA Last updated 1 November 2022

What this trial tests

NA trial testing Camrelizumab in Ovarian Clear Cell Carcinoma in 20 participants. Status unknown.

Timeline

30 October 2022

Primary endpoint
30 September 2023

28 February 2024

Quick facts

Lead sponsor	Peking University Third Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	30 October 2022
Primary completion	30 September 2023
Estimated completion	28 February 2024

Drugs / interventions tested

Camrelizumab — full drug profile →

Conditions studied

Ovarian Clear Cell Carcinoma — all drugs for Ovarian Clear Cell Carcinoma →

Sponsor

Peking University Third Hospital

Who can join

Adults 18 to 75, any sex, with Ovarian Clear Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is prospective ,open-label, single-center phase II clinical study. Target population is patients with advanced (stage III-IV) ovarian clear cell carcinoma. Study objective is to evaluate effectiveness response of Camrelizumab + anlotinib in subjects with advanced ovarian clear cell carcinoma Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Genetic and therapeutic heterogeneity shape the baseline and longitudinal immune ecosystem of ovarian clear cell carcinoma.
Xia S, Chen L, Yu M, Li J, et al · · 2024 · cited 13× · PMID 39608974 · DOI 10.1136/jitc-2024-010069
Tumor Immune Microenvironment and Checkpoint Inhibition in Clear Cell Ovarian Carcinoma: Bridging Tumor Biology and Clinical Application in Immunotherapy.
Borella F, Capella G, Cosma S, Gallio N, et al · · 2025 · PMID 41020848 · DOI 10.3390/cimb47090726

Verify or expand the search:

Other trials of Camrelizumab

Trials testing the same drug.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07466901 — A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Rad · NA · not yet recruiting
NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
NCT07266350 — A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for th · not yet recruiting

Other recruiting trials for Ovarian Clear Cell Carcinoma

Currently open trials in the same condition.

NCT06065462 — Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 · Phase 1, PHASE2 · recruiting
NCT06279104 — A Comparative Study of the Treatment of Real-world Patients With Clear Cell Carcinoma of the Ovary · recruiting
NCT05296512 — Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer · Phase 2 · active not recruiting
NCT04104776 — A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas · Phase 1, PHASE2 · recruiting

Other Peking University Third Hospital trials

Trials by the same sponsor.

NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05600998 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
Last refreshed: 1 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05600998.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing